Sanofi expands collaboration with SK Bioscience - European Biotechnology Magazine
Sanofi and SK Bioscience expand collaboration to develop next-gen PCVs for pediatric and adult populations, co-funding R&D. Sanofi pays €50m upfront, with success-dependent milestone payments. Sanofi to commercialize globally except South Korea, where SK Bioscience has exclusivity. Phase III testing of PCV21 vaccine begins next week. Despite vaccination programs, invasive pneumococcal disease persists, driving market growth.
Highlighted Terms
Related News
Sanofi and SK Bioscience expand collaboration to develop next-gen PCVs for pediatric and adult populations, co-funding R&D. Sanofi pays €50m upfront, with success-dependent milestone payments. Sanofi to commercialize globally except South Korea, where SK Bioscience has exclusivity. Phase III testing of PCV21 vaccine begins next week. Despite vaccination programs, invasive pneumococcal disease persists, driving market growth.